Recent findings from the NUTRITION human clinical trial (Natural Tocotrienol Against Ischemic Stroke Event)1 showed that supplementation with the tocotrienol EVNol Suprabio (from ExcelVite, based in Edison, NJ) may decrease aspirin resistance in patients taking blood thinning drugs. In the single-center, randomized double-blind clinical trial, 150 patients who suffered transient ischemic attacks or stroke in the previous six months were assigned to take either placebo, 400 mg of tocotrienol or 800 mg of tocotrienol in addition with aspirin or clopidogrel alone or in combination. While aspirin has been shown to reduce the relative risk of recurrent stroke by inhibiting platelet aggregation, some patients develop aspirin resistance, becoming resistant or only partially responsive to the antiplatelet effects.
